Multiagent Intratumoral Immunotherapy Can Be Effective in A20 Lymphoma Clearance and Generation of Systemic T Cell Immunity
暂无分享,去创建一个
Richard J. Simpson | Emmanuel Katsanis | K. Gilman | Dan W. Davini | Megan J. Cracchiolo | Andrew P. Matiatos | Amanda G. Moon
[1] Richard J. Simpson,et al. Murine precursors to type 1 conventional dendritic cells induce tumor cytotoxicity and exhibit activated PD-1/PD-L1 pathway , 2022, PloS one.
[2] D. Czerwinski,et al. Intratumoral immunotherapy relies on B and T cell collaboration , 2022, Science Immunology.
[3] D. Dingli,et al. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma , 2022, Blood advances.
[4] D. Czerwinski,et al. Neoadjuvant Intratumoral Immunotherapy with TLR9 Activation and Anti-OX40 Antibody Eradicates Metastatic Cancer. , 2022, Cancer Research.
[5] A. Titov,et al. Knowns and Unknowns about CAR-T Cell Dysfunction , 2022, Cancers.
[6] D. Hanahan. Hallmarks of Cancer: New Dimensions. , 2022, Cancer discovery.
[7] P. Allavena,et al. Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity , 2021, Journal for ImmunoTherapy of Cancer.
[8] P. Pérez-Galán,et al. Immunotherapies in Non-Hodgkin’s Lymphoma , 2021, Cancers.
[9] Z. Berneman,et al. A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy , 2021, Journal of Experimental & Clinical Cancer Research.
[10] M. Babjuk,et al. 100 years of Bacillus Calmette–Guérin immunotherapy: from cattle to COVID-19 , 2021, Nature Reviews Urology.
[11] I. Melero,et al. Intratumoural administration and tumour tissue targeting of cancer immunotherapies , 2021, Nature Reviews Clinical Oncology.
[12] A. Naranjo,et al. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032 , 2021, Clinical Cancer Research.
[13] H. Sultan,et al. Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration , 2020, Journal for ImmunoTherapy of Cancer.
[14] A. Anderson,et al. Tim-3 finds its place in the cancer immunotherapy landscape , 2020, Journal for immunotherapy of cancer.
[15] Kongming Wu,et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4 , 2019, Molecular Cancer.
[16] R. Wilkinson,et al. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies , 2019, Journal of Immunotherapy for Cancer.
[17] B. Heyman,et al. New developments in immunotherapy for lymphoma , 2018, Cancer biology & medicine.
[18] W. Loging,et al. Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial , 2018, Clinical Cancer Research.
[19] A. Naranjo,et al. A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931 , 2018, Front. Immunol..
[20] B. Fox,et al. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40 , 2017, Clinical Cancer Research.
[21] R. Ponce,et al. Local Delivery of OncoVEXmGM-CSF Generates Systemic Antitumor Immune Responses Enhanced by Cytotoxic T-Lymphocyte–Associated Protein Blockade , 2017, Clinical Cancer Research.
[22] J. Vermorken,et al. Immunotherapy in head and neck cancer: aiming at EXTREME precision , 2017, BMC Medicine.
[23] J. Wolchok,et al. Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells , 2017, Science Immunology.
[24] Ana C Anderson,et al. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. , 2016, Immunity.
[25] M. Mcnamara,et al. OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal , 2015, Front. Oncol..
[26] D. Schrijvers,et al. Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs. , 2015, Pharmacology & therapeutics.
[27] S. Hahn,et al. Activated MHC-mismatched T helper-1 lymphocyte infusion enhances GvL with limited GvHD , 2014, Bone Marrow Transplantation.
[28] Marco Antonio Ayala García,et al. The Major Histocompatibility Complex in Transplantation , 2012, Journal of transplantation.
[29] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[30] R. Tibshirani,et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Helen X. Chen,et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.
[32] J. Allison,et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors , 2010, Proceedings of the National Academy of Sciences.
[33] A. Bossler,et al. Oligodeoxynucleotide CpG 7909 Delivered as Intravenous Infusion Demonstrates Immunologic Modulation in Patients With Previously Treated Non-Hodgkin Lymphoma , 2006, Journal of immunotherapy.
[34] M. Mbow,et al. A pathway analysis of poly(I:C)-induced global gene expression change in human peripheral blood mononuclear cells. , 2006, Physiological Genomics.
[35] Xinchun Chen,et al. Peritransplantation vaccination with chaperone-rich cell lysate induces antileukemia immunity. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[36] M. Graner,et al. Chaperone-rich cell lysates, immune activation and tumor vaccination , 2006, Cancer Immunology, Immunotherapy.
[37] I. O-Sullivan,et al. Intratumoral injection of IL-secreting syngeneic/allogeneic fibroblasts transfected with DNA from breast cancer cells prolongs the survival of mice with intracerebral breast cancer , 2005, Cancer Gene Therapy.
[38] H. Feng,et al. Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity. , 2001, Blood.
[39] L. He,et al. Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[40] B. Blazar,et al. Effective immunization against neuroblastoma using double-transduced tumor cells secreting GM-CSF and interferon-gamma. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[41] E. Jaffee,et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[42] B. Benacerraf,et al. Effect of Bacillus Calmette-Guérin Infection on Transplanted Tumours in the Mouse , 1959, Nature.